Intuitive Surgical Inc Stock Price, News & Analysis

Jupiter Endovascular (ISRG) closed an oversubscribed Series B financing that surpassed its $40 million target, led by Sonder Capital with participation from Senvest Management, LB Investment, and a new strategic corporate investor. Proceeds will fund completion of the SPIRARE II pivotal trial, commercialization preparation, and new TFX applications. The announcement follows an FDA 510(k) clearance last month for the Vertex Catheter with TFX and precedes presentation of first-in-human SPIRARE I results at TCT on October 26, 2025. SPIRARE II plans to enroll up to 145 patients at up to 25 U.S. and European sites.

Intuitive (Nasdaq: ISRG) has unveiled new software capabilities for its da Vinci 5 robotic surgery system, leveraging its enhanced computing power that is 10,000 times greater than the previous da Vinci Xi model. The update introduces three key features: Force Gauge, a visual indicator showing real-time force applied during surgery; In-Console Video Replay, allowing surgeons to review procedure moments without leaving the console; and Network CCM, enabling remote software updates.

The Force Gauge feature measures force within a 0-6.5 Newton range, with published data suggesting reduced force application during procedures. These FDA-cleared features aim to enhance surgical precision, efficiency, and patient outcomes while reducing administrative burden through remote updates.

Intuitive Surgical's (NASDAQ:ISRG) da Vinci 5® robotic surgical system has been launched across all MemorialCare hospitals in Southern California, marking a significant expansion of advanced surgical capabilities. The system features 10,000 times more computing power than its predecessor and introduces over 150 design enhancements.

Key improvements include next-generation 3D imaging, Force Feedback technology that reduces tissue pressure by up to 43% in preclinical trials, and enhanced ergonomics. More than 120 surgeons across MemorialCare's three hospitals are trained to perform procedures in nine specialties using da Vinci platforms.

Intuitive (NASDAQ: ISRG) reported strong Q2 2025 financial results with revenue reaching $2.44 billion, up 21% year-over-year. The company's worldwide da Vinci procedures grew 17%, with 395 new system placements bringing the total installed base to 10,488 systems, a 14% increase from the previous year.

Key highlights include GAAP net income of $658 million ($1.81 per diluted share) and non-GAAP net income of $798 million ($2.19 per diluted share). The company secured important regulatory approvals, including European MDR certification and Japanese clearance for its da Vinci 5 surgical system.

For 2025, Intuitive projects worldwide da Vinci procedure growth of 15.5% to 17% and expects non-GAAP operating expense growth of 10% to 14%.

Intuitive (NASDAQ:ISRG), the robotic surgery pioneer, demonstrated groundbreaking telesurgery capabilities at the Society of Robotic Surgery conference in Strasbourg, France. Two surgeons, Dr. Doug Stoddard in Georgia and Dr. Andrea Pakula in France, successfully performed a transatlantic demonstration using a dual console da Vinci 5 system with Force Feedback technology.

The demonstration showcased remote surgical control capabilities across 4,000 miles, enabling surgeons to collaborate and share control of surgical instruments. CEO Dave Rosa emphasized that while telesurgery shows promise for improving patient access to minimally invasive care, the company prioritizes patient safety and practical value over technological advancement.

The demonstrated telesurgery software remains in development and is not yet FDA-cleared or CE marked. Intuitive has facilitated nearly 17 million da Vinci procedures and trained approximately 90,000 surgeons over its 30-year history.

Intuitive (Nasdaq: ISRG) has received FDA clearance for its new Vessel Sealer Curved, an advanced bipolar electrosurgical instrument designed for use with multiport da Vinci systems. The instrument represents a significant advancement in surgical technology, featuring a unique curved tip and fully wristed design for enhanced precision in minimally invasive procedures.

The device is FDA-cleared for sealing blood vessels up to 7mm in diameter and is notably the first of Intuitive's advanced energy instruments approved for lymphatic vessel transection. The curved jaw design follows natural anatomical contours, improving visibility and control in tight spaces. This milestone comes as Intuitive celebrates its 30th year in robotic-assisted technology, with nearly 17 million da Vinci procedures performed to date.

Intuitive (NASDAQ:ISRG) has received CE mark approval for its da Vinci 5 Surgical System in Europe, marking a significant milestone for the company's most advanced robotic-assisted surgical platform. The system is approved for both adult and pediatric use across abdominopelvic and thoracoscopic procedures.

The fifth-generation system features over 150 enhancements, including Force Feedback technology, an improved 3D vision system, and 10,000x more computing power. The platform has already received FDA clearance in 2024 for various procedures and joins Intuitive's portfolio of surgical systems that have been used in over 410,000 procedures in Europe in 2024 and nearly 17 million procedures worldwide.

Dan Larson, a former Boeing quality engineer diagnosed with lung cancer in 2023, shares his successful treatment journey using Intuitive's (ISRG) robotic surgical technology. At MultiCare Tacoma General Hospital, Larson underwent two robotic lung biopsies using the Ion Endoluminal System and a robotic-assisted lobectomy with the da Vinci 5 system. His story coincides with Intuitive's 30th anniversary in 2025. The company has facilitated nearly 17 million da Vinci procedures and trained about 90,000 surgeons. MultiCare Health System, an early adopter in the Pacific Northwest, operates 30 da Vinci systems, including four da Vinci 5's and four Ion systems. To commemorate Larson's visit, Intuitive employees raised $25,000 for St. Jude Children's Research Hospital through an Impact Wellness Challenge.

Intuitive (NASDAQ: ISRG) announced a significant leadership transition, with President Dave Rosa being promoted to CEO effective July 1, 2025. Current CEO Gary Guthart will become executive chair of the board, while current Board Chair Craig Barratt will transition to lead independent director.

Rosa, a 29-year veteran who joined Intuitive as its ninth employee in 1996, has held various leadership positions across engineering, clinical development, marketing, and commercial operations. His notable achievements include founding the company's clinical engineering and endoluminal groups, leading to the development of the da Vinci SP surgical system and Ion robotic bronchoscopy system.

Under Guthart's 15-year tenure as CEO, Intuitive has pioneered advancements in robotic-assisted surgery, with surgeons performing nearly 17 million da Vinci procedures and training approximately 90,000 surgeons on their systems.